Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.

Abstract:

:Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN). Besides direct antiviral effect, modulation of the immune system may be an additional benefit for telbivudine-treated patients. Indeed, there is much clinical data indicating an IFN-like behaviour for telbivudine in contrast to other oral nucleos(t)ides, such as high HBeAg seroconversion, similar hepatitis B surface antigen (HBsAg) decline and biphasic viral kinetics. Clinical studies, animal models and in vitro studies suggest that both the innate and adaptive immune system responses contribute to high HBeAg seroconversion during telbivudine treatment through modulation of the function and/or expression of CD4+/CD8+ T cells, Th1/Th2, Treg, PD-1/PD-L1, Th17, IL-21 and TFH. The results described in this review suggest that the antiviral effect of telbivudine may be attributable not only to direct suppression of hepatitis B virus, but also to immunoregulatory effects. Hypothetically, telbivudine shares some common signal pathways with IFN.

journal_name

J Viral Hepat

authors

Wang GQ,Ding YP,Dong YH

doi

10.1111/jvh.12059

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

9-17

eissn

1352-0504

issn

1365-2893

journal_volume

20 Suppl 1

pub_type

杂志文章,评审
  • Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.

    abstract::Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2011.01560.x

    authors: Mederacke I,Yurdaydin C,Großhennig A,Erhardt A,Cakaloglu Y,Yalcin K,Gurel S,Zeuzem S,Zachou K,Chatzikyrkou C,Bozkaya H,Dalekos GN,Manns MP,Wedemeyer H,Hep-Net\/International Delta Hepatitis Study Group.

    更新日期:2012-06-01 00:00:00

  • Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels.

    abstract::The role of hepatitis C virus (HCV) heterogeneity in the severity of chronic hepatitis C infection remains unclear. Our aim was to study the hypervariable region 1 (HVR1) heterogeneity in patients with chronic hepatitis C infected with genotype 1b or 3 and with normal or abnormal alanine aminotransferase (ALT). HVR1 q...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2002.00327.x

    authors: Asselah T,Martinot M,Cazals-Hatem D,Boyer N,Auperin A,Le Breton V,Erlinger S,Degott C,Valla D,Marcellin P

    更新日期:2002-01-01 00:00:00

  • Consistent high prevalence of undiagnosed blood-borne virus infection in patients attending large urban emergency departments in England.

    abstract::Understanding local viral hepatitis and HIV epidemiology is essential if WHO elimination targets are to be achieved. We demonstrate a consistently high prevalence of undiagnosed active infection in urban emergency department attendees in England, with variations in local risk groups crucial to informing targeted testi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13197

    authors: Hopkins MJ,Todd S,Beadsworth M,Anderson C,Mohamed Z,Muir D,Vivancos R,Brown AS,Ruf M,Chawla A

    更新日期:2020-01-01 00:00:00

  • Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

    abstract::Neumann et al. [1] developed a widely used model for the analysis of hepatitis C virus (HCV) dynamics after the initiation of interferon therapy that assumes the effectiveness of therapy in blocking virion production, epsilon, is constant. However, with pegylated interferon alpha-2b (PEG-IFN) given weekly, there are s...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00954.x

    authors: Shudo E,Ribeiro RM,Perelson AS

    更新日期:2008-05-01 00:00:00

  • Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure.

    abstract::Chronic hepatitis B virus (HBV)-infected patients with liver failure have a poor prognosis, and no satisfactory biomarkers are available for diagnosis before the end-stage. We explored serum peptide profiling for diagnosis and prediction of progression to liver failure in HBV-infected patients. Serum samples (164) fro...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01267.x

    authors: Han T,Liu H,Yu ZL,Li J,Wang L,Xiao SX,Li Y,Yu ML

    更新日期:2010-03-01 00:00:00

  • Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.

    abstract::One hundred and thirty-one post-liver transplantation patients with chronic hepatitis B and failing lamivudine therapy with detectable serum hepatitis B virus (HBV) deoxyribonucleic acid by hybridization assays or > or =1 x 10(6) copies/mL by polymerase chain reaction, and elevated alanine transaminase levels despite ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00578.x

    authors: Westland CE,Yang H,Delaney WE 4th,Wulfsohn M,Lama N,Gibbs CS,Miller MD,Fry J,Brosgart CL,Schiff ER,Xiong S

    更新日期:2005-01-01 00:00:00

  • Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group.

    abstract::Chronic non-A, non-B hepatitis (NANBH) is a common and often progressive liver disease. Based on current serological tests, hepatitis C virus (HCV) infection is responsible for most cases. Interferon-alpha (IFN) treatment at a dose of 3 x 10(6) units given three times per week for 24 weeks has been shown to be effecti...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.1994.tb00062.x

    authors: Davis GL,Lindsay K,Albrecht J,Bodenheimer HC Jr,Balart LA,Perrillo RP,Dienstag JL,Tamburro C,Schiff ER,Carey W

    更新日期:1994-01-01 00:00:00

  • Public health clinic-based hepatitis C testing and linkage to care in Baltimore.

    abstract::Testing and linkage to care are important determinants of hepatitis C virus (HCV) treatment effectiveness. Public health clinics serve populations at high risk of HCV. We investigated their potential to serve as sites for HCV testing, initiation of and linkage to HCV care. Cross-sectional study of patients accessing s...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12507

    authors: Falade-Nwulia O,Mehta SH,Lasola J,Latkin C,Niculescu A,O'Connor C,Chaulk P,Ghanem K,Page KR,Sulkowski MS,Thomas DL

    更新日期:2016-05-01 00:00:00

  • DNA methylation patterns of peroxisome proliferator-activated receptor gamma gene associated with liver fibrosis and inflammation in chronic hepatitis B.

    abstract::Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that regulates gene expression of inflammatory mediators in liver injury. Hepatitis B virus (HBV) suppresses the PPAR gamma-mediated transactivation in liver cancerous cell lines. However, the role of PPAR gamma in patients with chroni...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12048

    authors: Zhao Q,Fan YC,Zhao J,Gao S,Zhao ZH,Wang K

    更新日期:2013-06-01 00:00:00

  • Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.

    abstract::This study investigated the molecular and pharmacokinetic mechanisms of the enhanced antiviral efficacy associated with pegylated interferon (PEG-IFN) alpha-2b and ribavirin. The study involved comparing the expression of serial double-stranded RNA-activated protein kinase (PKR) before and during treatment in 26 PEG-I...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2006.00803.x

    authors: Asahina Y,Izumi N,Umeda N,Hosokawa T,Ueda K,Doi F,Tsuchiya K,Nakanishi H,Matsunaga K,Kitamura T,Kurosaki M,Uchihara M,Higaki M,Miyake S

    更新日期:2007-06-01 00:00:00

  • Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.

    abstract::The aim of this study was to evaluate the Chiron branched DNA (bDNA) assay for detection of serum hepatitis B virus (HBV) DNA in patients with chronic hepatitis B lacking hepatitis B e antigen (HBeAg) and undergoing interferon (IFN) therapy. Results obtained with the bDNA assay were compared with those obtained using ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00128.x

    authors: Habersetzer F,Zoulim F,Jusot JF,Zhang X,Trabaud MA,Chevallier P,Chevallier M,Ahmed SN,Sepetjan M,Comanor L,Minor J,Trépo C

    更新日期:1998-11-01 00:00:00

  • Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.

    abstract::Significant advances have been made, during the last 5 years, in the treatment of chronic hepatitis B. Several new antiviral agents: lamivudine, famciclovir, lobucavir and adefovir, have been shown to be safe and effective in inhibiting hepatitis B virus (HBV) replication. These compounds can be administered orally an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1999.00160.x

    authors: Hussain M,Lok AS

    更新日期:1999-05-01 00:00:00

  • Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China.

    abstract::Chronic hepatitis B infection is an important cause of liver-related mortality in China. This study assessed the efficacy and safety of entecavir in a heterogeneous patient population from a ‘real-world’ clinical practice setting in China. This prospective, observational cohort provides 48-week data on 2600 patients f...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12115

    authors: Hou JL,Jia JD,Wei L,Zhao W,Wang YM,Cheng M,Tang X,Tan DM,Ren H,Tang H,Cohen D,Llamoso C

    更新日期:2013-11-01 00:00:00

  • The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.

    abstract::Triple therapy with telaprevir, pegylated interferon and ribavirin has been reported to improve antiviral efficacy but have potentially severe adverse effects in patients with chronic hepatitis C. To avoid the severe effects of telaprevir, lowering the dose has been suggested. However, impact of dosage changes on anti...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12289

    authors: Oze T,Hiramatsu N,Yakushijin T,Yamada R,Harada N,Morishita N,Oshita M,Mita E,Ito T,Inui Y,Inada M,Tamura S,Yoshihara H,Imai Y,Kato M,Miyagi T,Yoshida Y,Tatsumi T,Kasahara A,Hayashi N,Takehara T

    更新日期:2015-03-01 00:00:00

  • Therapy of chronic hepatitis B: current challenges and opportunities.

    abstract::Better understanding of hepatitis B virus (HBV) replication, natural history and the immunopathogenesis of chronic hepatitis B, together with the introduction of effective agents with different mechanisms of action are the basis for better therapeutic strategies against chronic hepatitis B. Among currently available d...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2002.00388.x

    authors: Liaw YF

    更新日期:2002-11-01 00:00:00

  • Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia.

    abstract::Many Indigenous Australians in northern Australia living with chronic hepatitis B are unaware of their diagnosis due to low screening rates. A venous blood point of care test (POCT) or oral fluid laboratory test could improve testing uptake in this region. The purpose of this study was to assess the field performance ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13243

    authors: Sullivan RP,Davies J,Binks P,Dhurrkay RG,Gurruwiwi GG,Bukulatjpi SM,McKinnon M,Hosking K,Littlejohn M,Jackson K,Locarnini S,Davis JS,Tong SYC

    更新日期:2020-04-01 00:00:00

  • Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers.

    abstract::In 1996, a combined vaccine against both hepatitis A and B was licensed and commercialized and has been recommended for healthcare personnel in Belgium. This study compares the immunogenicity against hepatitis B virus (HBV) and safety of two vaccination schedules (0-1-12 months and 0-1-6 months) with this vaccine. Thi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2010.01365.x

    authors: De Schryver A,Verstrepen K,Vandersmissen L,Vandermeeren N,Vernaillen I,Vranckx R,Van Damme P,van Sprundel M

    更新日期:2011-04-01 00:00:00

  • Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*.

    abstract:SUMMARY:Treatment of hepatitis C virus (HCV) infection with interferon (IFN)-alpha, as monotherapy or in combination with ribavirin, is associated with significant side-effects including weight loss. The aim of our study was to describe the evolution of body weight during combination antiviral treatment and to examine ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00637.x

    authors: Seyam MS,Freshwater DA,O'Donnell K,Mutimer DJ

    更新日期:2005-09-01 00:00:00

  • The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics.

    abstract::Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.13040

    authors: Gill US,Kennedy PTF

    更新日期:2019-01-01 00:00:00

  • Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey.

    abstract::The World Health Organization has set the goal of reducing the hepatitis-related mortality rate by 65% between 2015 and 2030. Diagnosis and awareness of infection is the first essential step towards achieving this goal. Our study examined the current awareness rate of chronic viral hepatitis in the United States and t...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13060

    authors: Kim HS,Yang JD,El-Serag HB,Kanwal F

    更新日期:2019-05-01 00:00:00

  • Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

    abstract::This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients. These fiftee...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.1996.tb00094.x

    authors: Rasi G,Mutchnick MG,Di Virgilio D,Sinibaldi-Vallebona P,Pierimarchi P,Colella F,Favalli C,Garaci E

    更新日期:1996-07-01 00:00:00

  • Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

    abstract::Flares in chronic hepatitis B are often detrimental but sometimes lead to sustained immune control and disease remission. The aim of this study was to estimate the frequency of hepatitis flares which occur during and/or after cessation of nucleos(t)ide analogue (NA) therapy, and to assess their outcomes. In a single c...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01448.x

    authors: Zhang NP,Reijnders JG,Perquin M,Hansen BE,Janssen HL

    更新日期:2011-07-01 00:00:00

  • Five-year follow-up of immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina.

    abstract::Our study was conducted to further investigate the single-dose approach of hepatitis A vaccination, while providing supportive data on the flexibility of booster administration. Participants received at least one dose of Avaxim 80U Pediatric at 11-23 months of age, and they will be followed for 10 years. We report her...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12317

    authors: Espul C,Benedetti L,Linares M,Cuello H,Rasuli A

    更新日期:2015-04-01 00:00:00

  • Potential risk of zoonotic transmission from young swine to human: seroepidemiological and genetic characterization of hepatitis E virus in human and various animals in Beijing, China.

    abstract::The aim of this study was to further investigate the prevalence of infection and genotype of hepatitis E virus (HEV) among different species of animals, people whose works are related to pigs and the general population in the suburb of Beijing, China. Serum and faecal samples were collected from 10 animal species and ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01472.x

    authors: Geng J,Wang L,Wang X,Fu H,Bu Q,Liu P,Zhu Y,Wang M,Sui Y,Zhuang H

    更新日期:2011-10-01 00:00:00

  • Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.

    abstract::The study included 309 HIV-infected pregnant women receiving a lamivudine-containing antiretroviral regimen from week 25 of gestational age until 6 months postpartum, during breastfeeding. Twenty-seven of them (8.7%) were hepatitis B virus surface antigen (HBsAg) positive; at baseline, hepatitis B virus (HBV) DNA leve...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12301

    authors: Pirillo MF,Scarcella P,Andreotti M,Jere H,Buonomo E,Sagno JB,Amici R,Mancini MG,Leone P,Ceffa S,Mancinelli S,Marazzi MC,Vella S,Palombi L,Giuliano M

    更新日期:2015-03-01 00:00:00

  • An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.

    abstract::Single nucleotide polymorphisms (SNPs) in the interleukin 28B gene (IL28B) are good pretreatment predictors of anti-hepatitis C virus (HCV) therapy with interferon. SNPs of the inosine triphosphatase (ITPA) gene are associated with reduced haemoglobin levels during treatment with ribavirin. The i-densy™ (Arkray, Inc.)...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12026

    authors: Takahashi H,Mizuta T,Oeda S,Isoda H,Nakashita S,Kawaguchi Y,Izumi N,Hirai M,Kurose K,Iwane S,Eguchi Y,Kimura S,Anzai K,Ozaki I

    更新日期:2013-04-01 00:00:00

  • Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.

    abstract::It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analysed data from patie...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12723

    authors: Kim GA,Han S,Kim HD,An J,Lim YS

    更新日期:2017-11-01 00:00:00

  • New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India.

    abstract::Genome diversity is a hallmark of hepatitis B virus (HBV), which allowed its classification into 10 genotypes (A-J) and numerous subgenotypes. Among them, Genotype D is currently segregated into eight subgenotypes (D1-D8). Here, we report the identification and characterization of a novel subgenotype within genotype D...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01655.x

    authors: Ghosh S,Banerjee P,Deny P,Mondal RK,Nandi M,Roychoudhury A,Das K,Banerjee S,Santra A,Zoulim F,Chowdhury A,Datta S

    更新日期:2013-03-01 00:00:00

  • Estimating paediatric hepatitis C prevalence in the United States.

    abstract::Over 70 million individuals are infected with hepatitis C virus (HCV) worldwide. Yet most prevalence data are in the adult population, with little focus on paediatrics, partially due to the scarcity of public data. The objective of this paper is to examine HCV prevalence in children by estimating prevalence rates amon...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13377

    authors: Rahal H,Boutros S,Farhat M,Kullar R,Rahal K,Saab S

    更新日期:2020-12-01 00:00:00

  • Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.

    abstract::The Fas / Fas-ligand (FasL) system is an important death signal pathway in the liver. An enhanced local inflammatory response prompted by FasL expression, which contributes to neutrophil recruitment and interleukin-1 beta (IL-1beta) release, seems to be crucial to chronic liver damage, persistence of viral infections,...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.00974.x

    authors: Bortolami M,Kotsafti A,Cardin R,Farinati F

    更新日期:2008-07-01 00:00:00